Impact of primary negative symptoms on functional outcomes in schizophrenia

European Psychiatry

Volumn 29, Issue 7, 2014, Pages 449-455

  Fervaha, G ^a,b   Foussias, G ^a,b,c   Agid, O ^a,b,c   Remington, G ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Avolition Apathy; Functional outcome; Negative symptoms; Primary symptoms; Psychosocial functioning; Schizophrenia

Indexed keywords

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CALGARY DEPRESSION SCALE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG INDUCED DISEASE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FUNCTIONAL STATUS; HEINRICHS CARPENTER QUALITY OF LIFE SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; OBESITY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIMARY NEGATIVE SYNDROME; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; SCHIZOPHRENIA; SIMPSON-ANGUS SCALE; SOCIAL INTERACTION; SUBSTANCE ABUSE; WAIST CIRCUMFERENCE; ADOLESCENT; APATHY; MIDDLE AGED; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; YOUNG ADULT;

NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; APATHY; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84921450362     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2014.01.007     Document Type: Article

References (64)

1. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophr Res 1990, 3:247-251.
2. Addington D., Addington J., Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry 1993, 163:39-44.
3. Addington D., Addington J., Maticka-Tyndale E. Specificity of the Calgary Depression Scale for schizophrenics. Schizophr Res 1994, 11:239-244.
4. Andreasen N.C., Olsen S. Negative vs. positive schizophrenia. Definition and validation. Arch Gen Psychiatry 1982, 39:789-794.
5. Andreasen N.C. Improvement of negative symptoms: concepts, definition and assessment. Int Clin Psychopharmacol 1997, 12(Suppl.2):S7-S10.
6. Artaloytia J.F., Arango C., Lahti A., Sanz J., Pascual A., Cubero P., et al. Negative signs and symptoms secondary to antipsychotics: a double-blind, randomized trial of a single dose of placebo, haloperidol, and risperidone in healthy volunteers. Am J Psychiatry 2006, 163:488-493.
7. Blanchard J.J., Cohen A.S. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull 2006, 32:238-245.
8. Bobes J., Arango C., Garcia-Garcia M., Rejas J. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry 2010, 71:280-286.
9. Bozikas V.P., Kosmidis M.H., Kafantari A., Gamvrula K., Vasiliadou E., Petrikis P., et al. Community dysfunction in schizophrenia: rate-limiting factors. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:463-470.
10. Buchanan R.W., Kirkpatrick B., Heinrichs D.W., Carpenter W.T. Clinical correlates of the deficit syndrome of schizophrenia. Am J Psychiatry 1990, 147:290-294.
11. Carpenter W.T., Heinrichs D.W., Alphs L.D. Treatment of negative symptoms. Schizophr Bull 1985, 11:440-452.
12. Carpenter W.T., Heinrichs D.W., Wagman A.M. Deficit and non-deficit forms of schizophrenia: the concept. Am J Psychiatry 1988, 145:578-583.
13. Chatterjee A., Chakos M., Koreen A., Geisler S., Sheitman B., Woerner M., et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995, 152:1724-1729.
14. Collins A.A., Remington G., Coulter K., Birkett K. Depression in schizophrenia: a comparison of three measures. Schizophr Res 1996, 20:205-209.
15. Crow T.J. Molecular pathology of schizophrenia: more than one disease process?. Br Med J 1980, 280:66-68.
16. Evensen J., Rossberg J.I., Barder H., Haahr U., Hegelstad W., Joa I., et al. Apathy in first-episode psychosis patients: a ten year longitudinal follow-up study. Schizophr Res 2012, 136:19-24.
17. Faerden A., Friis S., Agartz I., Barrett E.A., Nesvag R., Finset A., et al. Apathy and functioning in first-episode psychosis. Psychiatr Serv 2009, 60:1495-1503.
18. Fenton W.S., McGlashan T.H. Testing systems for assessment of negative symptoms in schizophrenia. Arch Gen Psychiatry 1992, 49:179-184.
19. Fenton W.S., McGlashan T.H. Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. Am J Psychiatry 1994, 151:351-356.
20. Fervaha G., Foussias G., Agid O., Remington G. Amotivation and functional outcomes in early schizophrenia. Psychiatry Res 2013, 210:665-668.
21. Fervaha G., Remington G. Validation of an abbreviated quality of life scale for schizophrenia. Eur Neuropsychopharmacol 2013, 23:1072-1077.
22. First M.B. User's guide for the structured clinical interview for DSM-IV axis I disorders SCID-I: clinician version 1997, Amer Psychiatric Pub Inc, Washington, DC.
23. Flaum M., Andreasen N. The reliability of distinguishing primary versus secondary negative symptoms. Compr Psychiatry 1995, 36:421-427.
24. Fleischhacker W. Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction. Encephale 2000, 26(1):12-14.
25. Foussias G., Mann S., Zakzanis K.K., van Reekum R., Agid O., Remington G. Prediction of longitudinal functional outcomes in schizophrenia: the impact of baseline motivational deficits. Schizophr Res 2011, 132:24-27.
26. Galderisi S., Bucci P., Mucci A., Kirkpatrick B., Pini S., Rossi A., et al. Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome. Schizophr Res 2013, 147:157-162.
27. Gonul A.S., Kula M., Esel E., Tutus A., Sofuoglu S. A Tc-99m HMPAO SPECT study of regional cerebral blood flow in drug-free schizophrenic patients with deficit and non-deficit syndrome. Psychiatry Res 2003, 123:199-205.
28. Harvey P.D., Sabbag S., Prestia D., Durand D., Twamley E.W., Patterson T.L. Functional milestones and clinician ratings of everyday functioning in people with schizophrenia: overlap between milestones and specificity of ratings. J Psychiatr Res 2012, 46:1546-1552.
29. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984, 10:388-398.
30. Ho B.C., Nopoulos P., Flaum M., Arndt S., Andreasen N.C. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry 1998, 155:1196-1201.
31. Hogan T.P., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983, 13:177-183.
32. Horan W.P., Blanchard J.J. Neurocognitive, social, and emotional dysfunction in deficit syndrome schizophrenia. Schizophr Res 2003, 65:125-137.
33. Hunter R., Barry S. Negative symptoms and psychosocial functioning in schizophrenia: neglected but important targets for treatment. Eur Psychiatry 2012, 27:432-436.
34. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
35. Kelley M.E., van Kammen D.P., Allen D.N. Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am J Psychiatry 1999, 156:406-411.
36. Kirkpatrick B., Buchanan R.W., McKenney P.D., Alphs L.D., Carpenter W.T. The schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989, 30:119-123.
37. Kirkpatrick B., Ram R., Bromet E. The deficit syndrome in the Suffolk County Mental Health Project. Schizophr Res 1996, 22:119-126.
38. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull 2006, 32:214-219.
39. Konstantakopoulos G., Ploumpidis D., Oulis P., Patrikelis P., Soumani A., Papadimitriou G.N., et al. Apathy, cognitive deficits and functional impairment in schizophrenia. Schizophr Res 2011, 133:193-198.
40. Lahti A.C., Holcomb H.H., Medoff D.R., Weiler M.A., Tamminga C.A., Carpenter W.T. Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am J Psychiatry 2001, 158:1797-1808.
41. Leifker F.R., Patterson T.L., Heaton R.K., Harvey P.D. Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel. Schizophr Bull 2011, 37:334-343.
42. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
43. Lysaker P.H., Salyers M.P. Anxiety symptoms in schizophrenia spectrum disorders: associations with social function, positive and negative symptoms, hope and trauma history. Acta Psychiatr Scand 2007, 116:290-298.
44. Marder S.R., Davis J.M., Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997, 58:538-546.
45. Milev P., Ho B.C., Arndt S., Andreasen N.C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005, 162:495-506.
46. Miller D.D., Flaum M., Arndt S., Fleming F., Andreasen N.C. Effect of antipsychotic withdrawal on negative symptoms in schizophrenia. Neuropsychopharmacology 1994, 11:11-20.
47. Mohamed S., Rosenheck R., Swartz M., Stroup S., Lieberman J.A., Keefe R.S. Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am J Psychiatry 2008, 165:978-987.
48. Moller H.J., Muller H. Statistical differentiation between direct and indirect effects of neuroleptics on negative symptoms. Eur Arch Psychiatry Clin Neurosci 1997, 247:1-5.
49. Murphy B.P., Chung Y.C., Park T.W., McGorry P.D. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res 2006, 88:5-25.
50. Peralta V., Cuesta M.J., Martinez-Larrea A., Serrano J.F. Differentiating primary from secondary negative symptoms in schizophrenia: a study of neuroleptic-naive patients before and after treatment. Am J Psychiatry 2000, 157:1461-1466.
51. Peralta V., Moreno-Izco L., Sanchez-Torres A., Garcia de Jalon E., Campos M.S., Cuesta M.J. Characterization of the Deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs. Schizophr Bull 2014, 40:214-224.
52. Perlick D.A., Rosenheck R.A., Kaczynski R., Bingham S., Collins J. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia. Schizophr Res 2008, 99:192-199.
53. Pogue-Geile M.F., Harrow M. Negative symptoms in schizophrenia: their longitudinal course and prognostic importance. Schizophr Bull 1985, 11:427-439.
54. Rabinowitz J., Levine S.Z., Garibaldi G., Bugarski-Kirola D., Berardo C.G., Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr Res 2012, 137:147-150.
55. Remington G., Chong S.A., Kapur S. Distinguishing change in primary and secondary negative symptoms. Am J Psychiatry 1999, 156:974-975.
56. Rifkin A. Akinesia: a poorly recognized drug-induced extrapyramidal behavioral disorder. Arch Gen Psychiatry 1975, 32:672-674.
57. Rosenheck R., Leslie D., Keefe R., McEvoy J., Swartz M., Perkins D., et al. Barriers to employment for people with schizophrenia. Am J Psychiatry 2006, 163:411-417.
58. Rowland L.M., Spieker E.A., Francis A., Barker P.B., Carpenter W.T., Buchanan R.W. White matter alterations in deficit schizophrenia. Neuropsychopharmacology 2009, 34:1514-1522.
59. Schooler N.R. Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits. Acta Psychiatr Scand Suppl 1994, 380:21-26.
60. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970, 212:11-19.
61. Strauss G.P., Harrow M., Grossman L.S., Rosen C. Periods of recovery in deficit syndrome schizophrenia: a 20-year multi-follow-up longitudinal study. Schizophr Bull 2010, 36:788-799.
62. Stroup T.S., McEvoy J.P., Swartz M.S., Byerly M.J., Glick I.D., Canive J.M., et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003, 29:15-31.
63. Tamminga C.A., Thaker G.K., Buchanan R., Kirkpatrick B., Alphs L.D., Chase T.N., et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry 1992, 49:522-530.
64. Tracy K., Adler L.A., Rotrosen J., Edson R., Lavori P. Interrater reliability issues in multicenter trials. Part I: theoretical concepts and operational procedures used in Department of Veterans Affairs Cooperative Study #394. Psychopharmacol Bull 1997, 33:53-57.